A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization |
| |
Authors: | Tsutomu Tanaka Masafumi Ikeda Takuji Okusaka Hideki Ueno Chigusa Morizane Takashi Ogura Atsushi Hagihara Satoru Iwasa |
| |
Affiliation: | (1) Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku Tokyo, 104-0045, Japan |
| |
Abstract: | Introduction Transcatheter arterial embolization (TAE) has been recognized as an effective palliative treatment option for advanced hepatocellular
carcinoma (HCC). However, no effective alternative treatments for TAE-refractory HCC have yet been established. The aim of
this study was to evaluate the antitumor activity and toxicity of transcatheter arterial infusion chemotherapy using an epirubicin-Lipiodol
emulsion in patients with TAE-refractory HCC.
Methods Patients with TAE-refractory HCC were enrolled. A dose of 60 mg/m2 epirubicin emulsified in Lipiodol and contrast medium was administered from the feeding artery of the HCC. Treatment was
repeated every 4 to 12 weeks if there was no evidence of tumor progression or unacceptable toxicity.
Results Twenty patients were enrolled in this trial. The median number of treatment courses was 1 (range 1–4). Among the enrolled
patients, one (5%) achieved a partial response, and three (15%) showed a minor response. Five (25%) patients had no change
and 11 (55%) showed progressive disease. The median survival time, 1-year survival rate and median progression-free survival
time for the patients as a whole were 12.4 months, 52.6%, and 1.1 months, respectively. The main grade 3 and 4 toxicities
were leukocytopenia (35%), neutropenia (65%), thrombocytopenia (30%), and elevations of the aspartate aminotransferase (45%)
and alanine aminotransferase (35%) levels. These toxicities were generally brief and reversible.
Conclusion Transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion appears to have only modest activity with
moderate toxicity for treatment of patients with TAE-refractory HCC. These findings do not support its use in practice, and
further studies with the same regimen in patients with TAE-refractory HCC are not recommended. |
| |
Keywords: | Hepatocellular carcinoma Transcatheter arterial infusion chemotherapy Epirubicin Transcatheter arterial embolization |
本文献已被 PubMed SpringerLink 等数据库收录! |
|